Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment strategy for EGFR‐mutant lung cancers; however, resistance usually occurs due to a secondary mutation, T790M, in EGFR. Combination therapy using afatinib and cetuximab has had good results in lung tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudo, Kenichiro, Ohashi, Kadoaki, Makimoto, Go, Higo, Hisao, Kato, Yuka, Kayatani, Hiroe, Kurata, Yasuko, Takami, Yoichiro, Minami, Daisuke, Ninomiya, Takashi, Kubo, Toshio, Ichihara, Eiki, Sato, Akiko, Hotta, Katsuyuki, Yoshino, Tadashi, Tanimoto, Mitsune, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467494/
https://www.ncbi.nlm.nih.gov/pubmed/28388009
http://dx.doi.org/10.1002/1878-0261.12063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467494/
https://www.ncbi.nlm.nih.gov/pubmed/28388009
http://dx.doi.org/10.1002/1878-0261.12063

Ejemplares similares